Orchid Pharma Limited (BOM:524372)
India · Delayed Price · Currency is INR 773.10
-12.05 (-1.53%)
At close: Aug 22, 2025
Orchid Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
| 8,504 | 9,219 | 8,194 | 6,659 | 5,596 | 4,501 | Upgrade | |
Revenue Growth (YoY) | -3.45% | 12.52% | 23.05% | 19.00% | 24.33% | -6.97% | Upgrade |
Cost of Revenue | 4,928 | 5,442 | 5,032 | 4,013 | 3,271 | 2,413 | Upgrade |
Gross Profit | 3,576 | 3,777 | 3,162 | 2,646 | 2,325 | 2,088 | Upgrade |
Selling, General & Admin | 859.73 | 863.61 | 729.83 | 663.66 | 648.58 | 686.14 | Upgrade |
Other Operating Expenses | 1,728 | 1,742 | 1,323 | 1,145 | 1,145 | 817.22 | Upgrade |
Operating Expenses | 2,935 | 2,951 | 2,386 | 2,357 | 2,664 | 2,593 | Upgrade |
Operating Income | 641.03 | 826.3 | 776.25 | 289.93 | -338.9 | -504.94 | Upgrade |
Interest Expense | -142.99 | -145.4 | -163.55 | -322.26 | -320.12 | -513.36 | Upgrade |
Interest & Investment Income | - | - | 163.48 | 6.18 | 4.19 | 7.33 | Upgrade |
Earnings From Equity Investments | 40.22 | 38.99 | -28.98 | -21.54 | -35.23 | - | Upgrade |
Currency Exchange Gain (Loss) | - | - | 67.35 | 52.01 | 75.82 | 34.91 | Upgrade |
Other Non Operating Income (Expenses) | 313.52 | 274.75 | 77.8 | 126.6 | 4.9 | 4.81 | Upgrade |
EBT Excluding Unusual Items | 851.77 | 994.63 | 892.36 | 130.93 | -609.34 | -971.26 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | 0.15 | 5.12 | 19.42 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -1.88 | 7.75 | 0 | -0.65 | Upgrade |
Other Unusual Items | - | - | - | 392.1 | - | - | Upgrade |
Pretax Income | 851.77 | 994.63 | 890.47 | 530.93 | -604.21 | -952.49 | Upgrade |
Income Tax Expense | -0.39 | -1.94 | -31.19 | - | - | - | Upgrade |
Earnings From Continuing Operations | 852.17 | 996.57 | 921.67 | 530.93 | -604.21 | -952.49 | Upgrade |
Earnings From Discontinued Operations | - | - | - | -67.75 | 584.7 | -212.81 | Upgrade |
Net Income to Company | 852.17 | 996.57 | 921.67 | 463.18 | -19.51 | -1,165 | Upgrade |
Net Income | 852.17 | 996.57 | 921.67 | 463.18 | -19.51 | -1,165 | Upgrade |
Net Income to Common | 852.17 | 996.57 | 921.67 | 463.18 | -19.51 | -1,165 | Upgrade |
Net Income Growth | -23.99% | 8.13% | 98.98% | - | - | - | Upgrade |
Shares Outstanding (Basic) | 51 | 51 | 48 | 41 | 41 | 41 | Upgrade |
Shares Outstanding (Diluted) | 51 | 51 | 48 | 41 | 41 | 41 | Upgrade |
Shares Change (YoY) | 4.95% | 4.86% | 18.49% | - | - | 9914.82% | Upgrade |
EPS (Basic) | 16.80 | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 | Upgrade |
EPS (Diluted) | 16.80 | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 | Upgrade |
EPS Growth | -27.58% | 3.12% | 67.93% | - | - | - | Upgrade |
Free Cash Flow | - | -1,309 | 611.77 | -665.75 | 780.71 | 229.82 | Upgrade |
Free Cash Flow Per Share | - | -25.81 | 12.65 | -16.31 | 19.13 | 5.63 | Upgrade |
Gross Margin | 42.05% | 40.97% | 38.59% | 39.74% | 41.55% | 46.38% | Upgrade |
Operating Margin | 7.54% | 8.96% | 9.47% | 4.35% | -6.06% | -11.22% | Upgrade |
Profit Margin | 10.02% | 10.81% | 11.25% | 6.96% | -0.35% | -25.89% | Upgrade |
Free Cash Flow Margin | - | -14.20% | 7.47% | -10.00% | 13.95% | 5.11% | Upgrade |
EBITDA | 993.43 | 1,172 | 1,094 | 837.72 | 531.03 | 583.9 | Upgrade |
EBITDA Margin | 11.68% | 12.71% | 13.35% | 12.58% | 9.49% | 12.97% | Upgrade |
D&A For EBITDA | 352.39 | 345.46 | 317.72 | 547.79 | 869.93 | 1,089 | Upgrade |
EBIT | 641.03 | 826.3 | 776.25 | 289.93 | -338.9 | -504.94 | Upgrade |
EBIT Margin | 7.54% | 8.96% | 9.47% | 4.35% | -6.06% | -11.22% | Upgrade |
Revenue as Reported | 8,818 | 9,494 | 8,502 | 6,853 | 5,686 | 4,653 | Upgrade |
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.